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STUDIA MATHEMATICA
BULGARICA
NONPARAMETRIC VERSUS PARAMETRIC STATISTICAL
APPROACHES FOR GENETIC ANTICIPATION: THE
PANCREATIC CANCER CASE
Gleb R. Haynatzki Vera R. Haynatzka Randall E. Brand
Henry T. Lynch Simon A. Sherman1
Genetic anticipation for a particular disease can involve an earlier age of
onset, greater severity, and/or a higher number of affected individuals in
successive generations within a family. Comparison between nonparametric
and semiparametric tests is studied for matched data, and is one of the main
focuses of this study. This comparison is investigated for the variable age
of diagnosis among different birth cohorts, before and after adjustment for
time under observation. The comparison is illustrated on an example of
familial pancreatic cancer, which example is the second main focus of this
study. The nonparametric test performed on our example better than the
two semiparametric tests, and was less sensitive to right censoring. After
adjusting for follow up time, all methods detected genetic anticipation.
1. Introduction
Genetic anticipation can involve an earlier age at onset of hereditary/familial
disease, greater disease severity, and/or a higher number of affected individuals
in successive generations within a family. Different genetic mechanisms (e.g.
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trinucleotide repeat expansion) have been suggested to generate this phenomenon
for different diseases (e.g. familial leukaemia, lymphoma, Huntington’s disease,
myotonic dystrophy) [1]-[16]. Established anticipation provides cues to the nature
of the disease and facilitates prediction of age of disease onset. On the other hand,
it is an area of genetic epidemiology dealing with practical problems that do not
have easy and unquestionable solutions.
Serious dangers to the analysis of anticipation are posed by possible biases
from several sources. These are ascertainment bias (e.g. fecundity bias in
selection of probands parents with later age of onset while early diagnosed potential
parents are excluded or when children with early diagnosis are the probands while
later diagnosed children are excluded), difference in length of follow-up “at risk”
time between generations, effect of secular trends (e.g. increased smoking rate or
changing dietary habits or changing quality of health care). Additionally, possible
family-clustered structure of the data, i.e. intra-familial correlation due to shared
genotype and/or environment, as well as the information in the censored data
representing the unaffected family members have to be taken into account when
analyzing the data.
Pancreatic cancer is a deadly disease with average time to death after diagnosis
of less than ten months. This, in particular, means that age of diagnosis and age
of death are indistinguishable for the purpose of statistical analysis. There are
no early diagnostic tests for pancreatic cancer, and therefore established genetic
anticipation could improve the chances for early diagnosis of individuals and
their survival. Several studies claiming that genetic anticipation for pancreatic
cancer exists [17], [18] have been small and hence inadequate, whereas a more
recent one and of much larger sample size [19] has been more convincing. The
present study goes beyond purely theoretical comparison of advanced statistical
methods for anticipation. It focuses on their application to the case of familial
pancreatic cancer, and is an important step in establishing the presence of genetic
anticipation in this disease on firm scientific basis.
2. Methods and Results
Here we do not consider/detect disease severity but rather age of onset and
possible higher number of affected individuals in successive generations. The
disease we have used as an example in our analyses is pancreatic cancer whereas
the database is the Pancreatic Cancer Collaborative Registry (PCCR) maintained
at the University of Nebraska Medical Center.
Several standard statistical methods are usually used to test for genetic
anticipation:
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• Paired t -test for age at onset of affected parent-offspring pairs;
• Non-parametric ANOVA of age at onset of all affected on the predictor
– Generation (G1, G2, G3); or
– Cohort (C1, C2, C3);
• Survival analysis of type
– Semi-parametric (Cox proportional hazards model); or
– Non-parametric (log-rank test).
Unfortunately, both the paired t -test and the non-parametric ANOVA use
only the affected individuals whereas the information in the unaffected is left
unused. Both approaches are less powerful statistically and are prone to the
previously mentioned biases. Thus, the paired t -test, while incorporating the
family correlated structure to a certain degree, fails to do it in a systematic
way yielding biased estimates. For example, if there is an affected parent and
three affected children, the three matched affected parent-child pairs are treated
as independent whereas they are likely correlated. Furthermore, both the basic
Cox proportional hazards approach and the log-rank test are appropriate for
independent observations, thus ignoring completely the family correlated structure
of the data.
We have investigated the following methods that incorporate the family cor-
related structure and use the censored ages of unaffected individuals:
1. The non-parametric paired test by Hsu et al. [20], which is a generalization
of the log-rank test; and
2. Two semi-parametric methods
• Cox proportional hazards model with robust sandwich estimate of the
covariance matrix [21]; and
• Gamma frailty model [22].
The results yielded by these methods on a dataset of familial pancreatic cancer
are subsequently compared. Whereas both semi-parametric methods above have
been in use for some time, and are even implemented in statistical software,
Hsu’ non-parametric paired test [20] is less well-known. Therefore, we are briefly
sketching it next.
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2.1. Hsu’s Nonparametric Matched Test Statistic
Let (X, δ) be an index age and a disease indicator. That is, X is the age of
disease onset if the individual has the disease as indicated by δ = 1, and X is
the age at last follow-up or the age of death if the individual does not have the
disease as indicated by δ = 0, the latter case being a censored observation. Next,
consider K families with n1k individuals in the parental generation G1, and n2k
individuals in the children generation G2. For each family k (k = 1, . . . ,K), let
(X1ki, δ1ki) (i = 1, . . . , n1k) and (X2ki, δ2ki) (i = 1, . . . , n2k) be the index ages
and disease indicators for individuals from the kth family in generations G1 and
G2, respectively. It is further assumed that each matched pair has a different
baseline hazard function. The following notation has been used [20] to simplify
the expression for the test statistic:
Y¯1k(t) =
n1k∑
i=1
I(X1ki ≥ t),
Y¯2k(t) =
n2k∑
i=1
I(X2ki ≥ t),
Y¯k(t) = Y¯1k(t) + Y¯2k(t).
The left-hand side of the three equations above designate the number of
individuals in the kth family who are at risk for developing the disease at age t
in G1, G2, and in the two generations combined, respectively. Then the formula
for the matched test statistic will be
U1 = K
−1/2
K∑
k=1
[
n1k∑
i=1
δ1ki
Y¯2k(X1ki)
Y¯k(X1ki)
−
n2k∑
i=1
δ2ki
Y¯1k(X2ki)
Y¯k(X2ki)
]
,
which is the standardized sum of the weighted differences of affecteds between
generations G1 and G2. In particular, when no censored or tied data are present,
this test statistic is simply that for the sign test. The latter test uses the
proportion of pairs per family in which pairs the subject in generation G1 is
affected earlier than the one in generation G2. The variance of the test statistic
U1 is also shown in [20], and it is also known that U1 is asymptotically normal.
2.2. An Application to Pancreatic Cancer
The methods from the previous section have been applied to a subset of the
Pancreatic Cancer Collaborative Registry (only data of Evanston Northwestern
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Healthcare and Creighton University, Dr. Henry T. Lynchs Hereditary Cancer
Database) maintained at the University of Nebraska Medical Center in Omaha.
Families with at least two affected members and with verified Pancreatic Cancer
(PC) syndrome were included in the analyses. Either two consecutive generations
(G1 and G2) or just one (G1) per family were selected. For a family to provide two
generations, the younger (G2) had to include 1+ (affected or unaffected) member
of 65+ years, and the youngest such generation was named G2. Otherwise, if a
family had only one generation with members of 65+ years and with 1+ affected,
it was obviously the oldest generation affected from that family and was therefore
selected as generation G1 in the analyses. Thus, a total of 1,063 individuals from
52 families, with 12.6% affected, were analyzed. The statistical package SAS 9.1
(SAS Inst, Inc, Cary, NC, USA) was used in all calculations.
Figure 1: Distibution of time under observation, by generation.
Fig. 1 summarizes the median time under observation per generation, showing
that generation G1 (median = 77.0 years) has been observed longer than genera-
tion G2 (median = 63.0 years). This indicates that possible bias may be introdu-
ced in the data analyzes if no adjustment for time under observation is made.
We next estimated the hazard function for each generation using the life-table
approach, as shown on Fig. 2. The older generation, G1, has hazard function
smaller than the one for G2 up to and about age 63 years. However, it is obvious
that the relation between the two hazard functions is dependent on age, and it
changes after age 63 years, when the hazard function for G2 looks better than
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that for G1. On the other hand, estimates of the hazard function at larger ages
may be less stable and less reliable since more censored observations are present.
Figure 2: Hazard function estimated by the lifetable method.
We first compared the methods for detection of genetic anticipation by keeping
age as is, i.e. unrestricted. The values of the test statistic and the respective p-
values are shown below.
2.3. Comparing Methods: Unrestricted Age
The methods performed in this case as follows.
• Hsu’s nonparametric paired test:
– Z-score = 6.36, P-value < 0.0001
• Cox proportional hazards model with robust sandwich estimate of the
covariance matrix:
– Hazard Ratio (SE) = 1.13, P-value = 0.581
• Gamma frailty model:
– Hazard Ratio (SE) = 1.01, P-value = 0.976
Nonparametric Versus Parametric Approaches for Genetic Anticipation 117
The difference between Hsu’s nonparametric matched test and the two semi-
parametric tests is considerable, the former yielding statistically significant result,
whereas the latter two are far from significant at level of significance α = 0.05.
2.4. Comparing Methods: Age Restricted at 65 Years
In order to decrease the likely bias generated by difference in length of follow-
up “at risk” time between generations, similar to the approach in [19], we have
censored age at 65 years for all individuals, which also helped meet the proportio-
nal hazards assumption. This resulted in the following values of the respective
test statistic and its p-value.
• Hsu’s nonparametric paired test:
– Z-score = 6.70, P-value < 0.0001
• Cox proportional hazards model with robust sandwich estimate of the
covariance matrix:
– Hazard Ratio (SE) = 1.94, P-value = 0.0163
• Gamma frailty model:
– Hazard Ratio (SE) = 1.83, P-value = 0.0373
Now the results of the three tests are much more coherent, all being statistical-
ly significant at level of significance α = 0.05. Finally, the results clearly show
that Hsu’s nonparametric matched test is less sensitive to right censoring than
the two semiparametric methods, and is the method of choice at this stage of the
analyses.
3. Discussion
Here we do not consider/detect disease severity but rather age of onset and
possible higher number/incidence of affected individuals in successive generations.
In order to further focus just on age of onset, one has to adjust for disease
incidence in the cohort, as has been attempted in [23]. Our study found evidence
of anticipation in pancreatic cancer confirming the results from an even larger
study [19] while minimizing the effect of artifacts. We used data from the
Pancreatic Cancer Collaborative Registry (PCCR) maintained at the University
of Nebraska Medical Center. The PCCR is a recently created international
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database comprising data from several medical centers based in the United States
and Europe.
Our comparison of Hsu’s nonparametric matched test [20] with the two semi-
parametric methods [21], [22] showed that both allow heterogeneity of disease and
genetic prevalence across families by stratifying the subjects by families. Also,
neither approach makes distributional assumptions about age of onset. However,
the semi-parametric methods require the proportional hazards assumption. Inclu-
sion of time-dependent covariates may improve the model fit for the semiparamet-
ric methods. On the other hand, it is difficult to adjust for covariates in the non-
parametric approach. The results clearly show that Hsu’s nonparametric matched
test is less sensitive to right censoring than the two semiparametric methods,
and is the method of choice at this stage of the analyses. However, further
improvements in the semiparametric approaches may change this situation if their
sensitivity to censoring is considerably improved and the available information is
utilized more efficiently.
Age at onset may appear to decrease at subsequent generations due to cohort
effects. These could arise from changes in environmental, treatment and diagnostic
factors. Other competing risks or secular (i.e. non genetic anticipation) trends
may also be present. Some of these trends may be in reverse direction of anticipa-
tion, and decreasing it. Smoking is the only confirmed environmental risk factor
for both sporadic and familial pancreatic cancer. However, there are several
genetic mutations, including germline mutations in the BRCA2 gene, that have
been identified as risk factors and these may occur in up to 20% of familial
pancreatic cancer families [24], [25].
Our results are preliminary, and we currently work on further developing both
the database and the methods used. In particular, we would like to extend the
capabilities of the described nonparametric methods to incorporate covariates.
We also work on testing a wider set of approaches for genetic anticipation to an
augmented PCCR database.
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